Physician profile
Isha Gupta
NPI 1972980332
$11,440.35
in general payments reported to CMS, 2019-2025
29 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,632 · 2020: $318 · 2021: $1,651 · 2022: $1,001 · 2023: $953 · 2024: $2,053 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,839.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,484.48 | 2019-2025 | Centurion, Clareon, Hydrus Microstent |
| New World Medical,INC. | $2,185.82 | 2019-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Sight Sciences, INC. | $1,294.90 | 2019-2024 | Omni Surgical System |
| Glaukos Corporation | $802.13 | 2019-2025 | Istent Trabecular Micro-Bypass System Model Is3, Photrexa Cross-Linking Kit, Idose |
| Aerie Pharmaceuticals, INC. | $732.09 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $564.71 | 2019-2021 | |
| Abbvie INC. | $523.38 | 2023-2025 | |
| Allergan, INC. | $501.48 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $297.07 | 2022-2025 | Stellaris, Xiidra, Miebo |
| Ivantis, INC | $280.81 | 2019-2021 | |
| Alimera Sciences, INC. | $221.80 | 2019 | |
| Akorn Operating Company LLC | $160.57 | 2021 | |
| Eyevance Pharmaceuticals LLC | $142.46 | 2020-2021 | |
| Rxsight INC | $142.15 | 2022 | |
| Kala Pharmaceuticals, INC. | $136.13 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $134.70 | 2024-2025 | Eylea Hd |
| Iridex Corporation | $128.94 | 2019 | |
| Mallinckrodt Enterprises LLC | $122.51 | 2019 | |
| Genentech USA, INC. | $122.09 | 2024 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $90.14 | 2019 | |
| Sun Pharmaceutical Industries INC. | $79.24 | 2021-2025 | Cequa, Xelpros |
| Thea Pharma INC. | $56.47 | 2022-2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $51.00 | 2022-2023 | |
| Apellis Pharmaceuticals, INC. | $47.47 | 2025 | Syfovre |
| Dompe US, INC. | $45.30 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $31.45 | 2025 | Xdemvy |
| Akorn, INC. | $26.07 | 2020 | |
| Horizon Therapeutics Plc | $19.16 | 2023 | Tepezza |
| Ocular Therapeutix, INC. | $15.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isha Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.